DB:7R8

Stock Analysis Report

Executive Summary

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer.


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Replimune Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 7R8 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-1.3%

7R8

-2.3%

DE Biotechs

-0.2%

DE Market


1 Year Return

28.1%

7R8

8.4%

DE Biotechs

13.7%

DE Market

Return vs Industry: 7R8 exceeded the German Biotechs industry which returned 8.4% over the past year.

Return vs Market: 7R8 exceeded the German Market which returned 13.7% over the past year.


Shareholder returns

7R8IndustryMarket
7 Day-1.3%-2.3%-0.2%
30 Day-8.9%-3.2%0.3%
90 Day26.4%6.3%3.7%
1 Year28.1%28.1%8.6%8.4%17.2%13.7%
3 Yearn/a44.5%42.9%15.4%5.3%
5 Yearn/a13.0%10.6%21.3%4.7%

Price Volatility Vs. Market

How volatile is Replimune Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Replimune Group undervalued compared to its fair value and its price relative to the market?

3.12x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: 7R8 (€15.3) is trading above our estimate of fair value (€12.55)

Significantly Below Fair Value: 7R8 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 7R8 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 7R8 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 7R8's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 7R8 is good value based on its PB Ratio (3.1x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Replimune Group forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-23.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 7R8 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 7R8 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 7R8 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 7R8's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 7R8's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 7R8's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Replimune Group performed over the past 5 years?

-40.2%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: 7R8 is currently unprofitable.

Growing Profit Margin: 7R8 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 7R8's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 7R8's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 7R8 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 7R8 has a negative Return on Equity (-22.01%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Replimune Group's financial position?


Financial Position Analysis

Short Term Liabilities: 7R8's short term assets ($190.9M) exceed its short term liabilities ($14.2M).

Long Term Liabilities: 7R8's short term assets ($190.9M) exceed its long term liabilities ($38.6M).


Debt to Equity History and Analysis

Debt Level: 7R8's debt to equity ratio (4.9%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 7R8's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: 7R8 has a high level of physical assets or inventory.

Debt Coverage by Assets: 7R8's debt is covered by short term assets (assets are 19.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 7R8 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 7R8 has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of -66% each year.


Next Steps

Dividend

What is Replimune Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 7R8's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 7R8's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 7R8's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 7R8's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 7R8's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Philip Astley-Sparke (48yo)

0.08yrs

Tenure

US$1,812,591

Compensation

Mr. Philip Astley-Sparke, FSA, is a Co-founder of Replimune Group, Inc. and serves as its Executive Chairman since 2015. Mr. Astley-Sparke is Secretary and Treasurer at Replimune Group, Inc. and serves as  ...


CEO Compensation Analysis

Compensation vs Market: Philip's total compensation ($USD1.81M) is above average for companies of similar size in the German market ($USD1.19M).

Compensation vs Earnings: Philip's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Philip Astley-Sparke
Executive Chairman0.08yrsUS$1.81m3.7% $21.5m
Robert Coffin
Founder5.1yrsUS$2.27m6.05% $35.1m
Colin Love
Chief Operating Officer4.3yrsUS$1.30m2.87% $16.7m
Jean Franchi
Chief Financial Officer0.2yrsno datano data
Stephen Gorgol
Chief Accounting Officer0yrsno datano data
Pamela Esposito
Chief Business Officer4.3yrsUS$601.20k0.31% $1.8m

4.3yrs

Average Tenure

53.5yo

Average Age

Experienced Management: 7R8's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Philip Astley-Sparke
Executive Chairman0.08yrsUS$1.81m3.7% $21.5m
Robert Coffin
Founder5.1yrsUS$2.27m6.05% $35.1m
Joseph Slattery
Lead Independent Director0.9yrsUS$158.83k0.018% $105.6k
Jason Rhodes
Independent Director4.4yrsUS$151.26k1.72% $10.0m
Hugo Slootweg
Independent Director5.1yrsUS$144.48kno data
Otello Stampacchia
Independent Director4.8yrsUS$117.59kno data
Hyam Levitsky
Independent Non-Executive Director1.8yrsUS$262.53kno data
Kapil Dhingra
Independent Director2.6yrsUS$156.16kno data
Dieter Weinand
Independent Director1.7yrsUS$262.65kno data

4.4yrs

Average Tenure

54yo

Average Age

Experienced Board: 7R8's board of directors are considered experienced (4.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 95.7%.


Top Shareholders

Company Information

Replimune Group, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Replimune Group, Inc.
  • Ticker: 7R8
  • Exchange: DB
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$626.274m
  • Listing Market Cap: US$580.306m
  • Shares outstanding: 36.65m
  • Website: https://www.replimune.com

Number of Employees


Location

  • Replimune Group, Inc.
  • 18 Commerce Way
  • Woburn
  • Massachusetts
  • 1801
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
REPLNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2018
7R8DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2018

Biography

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. It is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 23:10
End of Day Share Price2020/02/20 00:00
Earnings2019/12/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.